Advanced Search

Study Preview



Study Title and Description

The efficacy and safety of solifenacin in patients with overactive bladder syndrome.



Key Questions Addressed
1 KQ 1: What are the benefits and harms of nonpharmacological treatments of UI in women, and how do they compare with each other? KQ 2: What are the benefits and harms of pharmacological treatments of UI in women, and how do they compare with each other? KQ 3: What are the comparative benefits and harms of nonpharmacological versus pharmacological treatments of UI in women? KQ 4: What are the benefits and harms of combined nonpharmacological and pharmacological treatment of UI in women?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title The efficacy and safety of solifenacin in patients with overactive bladder syndrome.
Author Oresković S., But I., Banović M., Goldstajn MS.
Country University of Zagreb, School of Medicine, Department of Gynecology and Obstetrics, Zagreb, Croatia.
Year 2012
Numbers Pubmed ID: 22816227

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: All studies
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
Country/countries
  • Comments Comments (
    0
    ) |
Inclusion criteria
  • Comments Comments (
    0
    ) |
Exclusion criteria
  • Comments Comments (
    0
    ) |
UI type
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Age
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Men included
  • Comments Comments (
    0
    ) |
Special populations
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Race
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Notes
  • Comments Comments (
    0
    ) |
Study years
  • Comments Comments (
    0
    ) |
Trial name (if given) nd
  • Comments Comments (
    0
    ) |
Does this paper cite a previous paper from the same study?
  • Comments Comments (
    0
    ) |


Baseline Characteristics
Question Total Comments
AnswerFollow-up
Participant flow No data entered.
Notes No data entered.



Results & Comparisons

No Results found.

Quality Dimensions
Dimension Value Notes Comments
RCT:.....Adequate generation of a randomized sequence
  • Comments Comments (
    0
    ) |
RCT:.....Allocation concealment
  • Comments Comments (
    0
    ) |
RCT:.....Blinding of PATIENTS
  • Comments Comments (
    0
    ) |
RCT.....Intention-to-treat-analysis
  • Comments Comments (
    0
    ) |
ALL.....Blinding of OUTCOME ASSESSORS (or "DOUBLE BLIND")
  • Comments Comments (
    0
    ) |
ALL.....Incomplete results data (attrition bias)
  • Comments Comments (
    0
    ) |
ALL....Group similarity at baseline (selection bias)
  • Comments Comments (
    0
    ) |
ALL.....Compliance with interventions
  • Comments Comments (
    0
    ) |
NRCS.....Patients in different intervention groups selected in an equivalent manner
  • Comments Comments (
    0
    ) |
NRCS....Baseline differences between groups accounted for (Adjusted analysis)?
  • Comments Comments (
    0
    ) |
ALL.....Other issues
  • Comments Comments (
    0
    ) |
ALL....Were interventions adequately described?
  • Comments Comments (
    0
    ) |

Quality Rating
No quality rating data was found.